Forward Therapeutics
forward-tx.com
Actively hiring
Professional Services
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
RA Capital Management, OrbiMed
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
OrbiMed Similar startupsby what they do, their industry and backers
At CubeFabs we are building AI factories to scale novel materials from lab to production.
ABOUT US Our Mission To design and build engineered protein therapeutics with our AI-native platform, transforming what's possible in…
Antire is an industry focused AI company for energy and ocean. We help organizations transform complex operations. Proven in critical…
GIVAX is developing a new class of vaccines to protect children from severe gastroenteritis caused by rotavirus and norovirus. Leveraging…
Chemical.AI’s software leverages AI to help scientists uncover innovative synthetic pathways for both novel and established target…
BioSqueeze engineers the subsurface with field-proven biomineralization that strengthens soils, seals fluid pathways and heals critical…
News
Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical Development
PALM BEACH GARDENS, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (
Read more
Report
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor
PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (
Read more
Report
Forward Therapeutics: $50 Million Raised To Develop Small Molecule Therapies For Immunological And Inflammatory Disorders
Forward Therapeutics - a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders - recently announced a$50 millionSeries A financing. The funding was led by BVF Partners LP with pa
Read more
Report